Accurate Liability Estimation Improves Power in Ascertained Case Control
  Studies by Weissbrod, Omer et al.
1 
 
Accurate Liability Estimation Improves Power in Ascertained Case Control 
Studies 
Omer Weissbrod
1
, Christoph Lippert
2
, Dan Geiger
3 
and David Heckerman
4
 
1
Computer Science Department, Technion - Israel Institute of Technology, Haifa, 
Israel 
2
eScience Group, Microsoft Research, Los Angeles, USA 
3
Computer Science Department, Technion - Israel Institute of Technology, Haifa, 
Israel 
4
eScience Group, Microsoft Research, Los Angeles, USA 
Corresponding Author: David Heckerman 
 
Abstract 
 
Linear mixed models (LMMs) have emerged as the method of choice for confounded 
genome-wide association studies. However, the performance of LMMs in non-
randomly ascertained case-control studies deteriorates with increasing sample size. 
We propose a framework called LEAP (Liability Estimator As a Phenotype; 
https://github.com/omerwe/LEAP) that tests for association with estimated latent 
values corresponding to severity of phenotype, and demonstrate that this can lead to a 
substantial power increase. 
Main Text 
In recent years, genome-wide association studies (GWAS) have uncovered thousands 
of risk variants for genetic traits
1
. Only a small fraction of disease variance is 
explained by discovered variants, possibly because contemporary sample sizes are 
relatively small and that causal variants tend to have small effect sizes2. To identify 
such variants, future studies will need to include hundreds of thousands of 
individuals. 
Population structure and family relatedness3 lead to spurious results and increased 
type I error rate. As sample sizes continue to increase, this difficulty becomes even 
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more severe, because larger samples are more likely to include individuals with a 
different genetic ancestry, or related individuals.  
Recently, LMMs have emerged as the method of choice for GWAS, due to their 
robustness to diverse sources of confounding
3
. LMMs gain resilience to confounding 
by testing for association conditioned on pairwise kinship coefficients between study 
subjects. Although designed for continuous phenotypes, LMMs have been 
successfully used in several large case-control GWAS
4-6
, because alternative methods 
cannot capture diverse sources of confounding
3
.  
However, LMMs in ascertained case-control studies, wherein cases are oversampled 
relative to the disease prevalence, lose power with increasing sample size compared to 
alternative methods
7
. This loss is due to several model violations: Dependence 
between tested causal variants and variants used to estimate kinship, dependence 
between genetic and environmental effects, and use of a non-continuous trait 
(Supplementary Note). Thus, the use of LMMs resolves the difficulty of sensitivity 
to confounding, but leads to a different difficulty instead. 
A possible remedy is to test for associations with a model that directly represents the 
case-control phenotype and takes the ascertainment scheme into account 
(Supplementary Note). Such models assume that observed case-control phenotypes 
are generated by an unobserved stochastic process with a well-defined distribution. 
One prominent example is the liability threshold model
8
, which associates individuals 
with a latent normally distributed variable called the liability, such that cases are 
individuals whose liability exceeds a given cutoff. Despite their elegance, such 
models are extremely computationally expensive, rendering whole genome 
association tests infeasible in most circumstances. 
As an alternative, we propose approximating such models by first estimating latent 
liability values and model parameters conditional on phenotypes, genotypes and 
disease prevalence, and then testing for association with the estimated liabilities via an 
LMM (Online Methods). LEAP is motivated by the observation that cases of rare 
diseases have a sharply peaked liability distribution (Supplementary Fig. 1), leading 
to highly accurate liability estimation (Supplementary Note). When testing for 
association in ascertained case-control studies, LEAP yields substantially increased 
power over naïve LMMs while remaining resilient to confounding because it largely 
compensates for the violations listed above. 
LEAP bears similarities to several recent methods for estimating the portion of the 
liability that is explained by a small set of explanatory variables
9, 10
.  Unlike these 
methods, LEAP estimates liabilities using the entire genome (Supplementary Note). 
In parallel work, Hayeck et al. proposed another framework called LTMLM (liability 
threshold mixed linear model) for association testing in ascertained case-control 
studies
11
. Both LTMLM and LEAP first estimate latent liability values and then test 
for association with these estimates. However, LTMLM tests for association with the 
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posterior mean of the liabilities in a score test framework, whereas LEAP tests for 
association with a maximum a posteriori (MAP) estimate, which is often more robust 
to model violations and can be evaluated at a substantially reduced computational cost 
(Online Methods and Supplementary Note). 
We evaluated the performance of LEAP on synthetic and real data sets, using the 
following methods for comparison: (i) LEAP, (ii) a standard LMM, (iii) a linear 
regression test using ten principal component (PC) covariates
12
 (denoted 
Linreg+PCs), and (iv) a univariate linear regression test (Linreg) without PC 
covariates, used as a baseline measure. Linreg+PCs and Linreg use the linear link 
function to prevent evaluation bias due to using a different link function. Experiments 
using logistic regression yielded results very similar to those with Linreg (data not 
shown).  
Sensitivity to confounding was evaluated by measuring type I error rates for synthetic 
data sets (Supplementary Note). We evaluated various combinations of population 
structure (quantified via the FST measure
13
) and family relatedness (measured via the 
fraction of sibling pairs), using FST levels of 0, 0.01 and 0.05, and sib-pair fractions of 
0%, 3% and 30%. Only LEAP and a standard LMM properly controlled for type I 
error in the presence of confounding (Supplementary Figs. 2 and 3 and 
Supplementary Table 1). 
The power of the methods was evaluated according to the distribution of test statistics 
of causal variants
9, 10—normalized according to the type I error rate—to prevent 
Linreg and Linreg+PCs from falsely appearing to be more powerful than other 
methods due to inflation of P values (Supplementary Note). 
To investigate the effects of sample size and ascertainment on power, we generated 
ascertained case-control data sets with prevalence of 0.1%, 1% and 10%, and sample 
sizes in the range 2,000-10,000. The advantage of LEAP over a standard LMM 
increased with sample size and with decreasing prevalence (Fig. 1 and 
Supplementary Figs. 4 and 5). In simulated samples with 0.1% prevalence and 
10,000 individuals, LEAP gained an average increase of over 20% in test statistics of 
causal variants (Fig. 1), and a power increase of over 5% for significance thresholds 
smaller than 5 10-5 (Supplementary Fig. 4). LEAP also outperformed other methods 
under more complex ascertainment schemes (Supplementary Note). We further 
verified that the increased power of LEAP stems from its accurate liability estimation 
in the presence of ascertainment (Supplementary Fig. 6 and Supplementary Note). 
Accurate liability estimation depends on the fraction of liability variance that is driven 
by genetic factors, called the narrow-sense heritability
2
. A higher heritability is 
expected to improve estimation accuracy, because more of the liability signal can be 
inferred from observed variants. We empirically verified that the advantage of LEAP 
over other methods increased with heritability, with noticeable power gains for 
diseases with heritability ≥25% (Fig. 1 and Supplementary Fig. 7). We also 
performed a series of experiments to demonstrate that LEAP outperforms other 
methods under diverse levels of population structure, family relatedness, polygenicity 
and covariate effects (Supplementary Figs. 8-15 and Supplementary Note). 
To evaluate performance on real data, we analyzed nine disease data sets from the 
Wellcome Trust case control consortium (WTCCC)
5, 14, 15
.  Measuring power for real 
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data sets is an inherently difficult task because the identities of true causal single 
nucleotide polymorphisms (SNPs) are unknown. Evaluating type I error rates for real 
data is also a difficult task, because inflation of P values may stem from either 
sensitivity to confounding, or from high polygenicity of the studied trait
16
. 
As an approximate measure for type I error, we verified that the proportion of SNPs 
having p<0.05 and p<10
-5
, and that are not within 2 Mbp of SNPs reported to be 
associated with the disease in previous studies, is comparable under LEAP and under 
a standard LMM. As an approximate measure for power, we computed normalized 
test statistics for SNPs that tag known risk variants from the US National Human 
Genome Research Institute catalog
17
 as a 'bronze standard'. 
LEAP demonstrated robustness to confounding, and was significantly more powerful 
than a standard LMM (P<0.05) in five out of the six rare phenotypes, with prevalence 
less than 1% (Fig. 2 and Supplementary Tables 2 and 3; results for hypertension are 
omitted from Fig. 2 owing to the low number of known risk variants). As expected 
from the simulations, the advantage of LEAP increased with sample size and with 
confounding. Thus, only a small advantage was observed in the WTCCC1 data sets, 
which contain about 4,500 individuals per data set and little population structure or 
family relatedness, whereas a significantly greater advantage was observed in the 
larger and more confounded WTCCC2 data sets.  
In the highly confounded multiple sclerosis (MS) data set
5
, LEAP obtained a mean 
increase of more than 8% over an LMM in test statistics of tag SNPs, and an even 
greater advantage over other methods, while demonstrating robustness to 
confounding. All genome-wide significant loci identified by LEAP and LMM, having 
p<5 10-8, have previously been reported to be associated with MS in meta-analyses. 
In contrast, Linreg+PCs and Linreg identified 2 and 508 previously unidentified 
significant loci, respectively. 
There are several avenues for future research. First, liabilities follow a truncated 
multivariate normal distribution, and thus their likelihood cannot be computed by an 
LMM without model misspecification, even if they are perfectly estimated.  It may be 
possible to modify the objective function of LEAP so that its estimated liabilities 
follow a normal distribution
18
. Second, liability estimation may be improved by 
improving kinship estimation in ascertained studies (Supplementary Note). Finally, 
liability estimation may be improved by adopting richer models with a heterogeneous 
effect-size variance
19, 20
. 
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Figures 
 
 
Figure 1: Synthetic data demonstrating that the power of LEAP increases with 
sample size and disease heritability. The values shown are the mean ratio of 
normalized test statistics for causal SNPs between each evaluated method and a 
standard LMM, under different sample sizes (top row) and heritability levels (bottom 
row), and 95% confidence intervals. Larger mean ratios indicate higher power. Values 
above the horizontal line indicate that a method has test statistics that are on average 
greater than that of a standard LMM. 
 
 
7 
 
 
Figure 2: Analysis of real data sets with LEAP and other methods. The values shown 
are the mean ratio of normalized test statistics of SNPs tagging known variants 
between each evaluated method and a standard LMM, and its 95% confidence 
interval. A higher mean ratio indicates higher power. Values above the horizontal line 
indicate that a method has test statistics that are on average greater than that of a 
standard LMM. The number of tag SNPs is 44, 38, 20, 11, 19, 35, 17, and 15 for 
multiple sclerosis (MS), Crohn's disease (CD), ulcerative colitis (UC), type 1 diabetes 
(T1D), bipolar disorder (BD), rheumatoid arthritis (RA), type 2 diabetes (T2D), and 
coronary artery disease (CAD), respectively.  The prevalence of each disease is shown 
below its name (in percent units). 
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Online Methods 
 
LEAP Overview 
The LEAP procedure is composed of four parts, which are now briefly overviewed, 
with detailed explanations following below. 
1. Heritability estimation: The heritability of a trait quantifies the degree to 
which it is driven by genetic factors
2, 21, 22
. Several methods for heritability 
estimation in case-control studies have been proposed recently
2, 22
. We adopt 
the method of ref.
2
, which directly models the ascertainment procedure. 
2. Liability estimation:  Using the heritability estimate, we fit a regularized 
Probit model, to estimate the effect size of each genetic variant on the liability. 
We use the Probit model to estimate liabilities for the sample individuals. 
3. Association testing: The liability estimate is used as an observed phenotype in 
a GWAS context. Genetic variants are tested for association with this estimate 
via a standard LMM. The LMM is fitted using the heritability estimate, as 
described below. 
We first provide a brief overview of the liability threshold model, and then derive a 
corresponding liability estimation model. Detailed derivations are found in the 
Supplementary Note. 
 
The Liability Threshold Model 
According to the liability threshold model, every individual i is associated with a 
latent normally distributed variable li~N(0,1), such that cases are individuals with li>t, 
where t is the liability cutoff for a particular trait of interest. Assuming a trait with a 
population prevalence K, t is given by         , where        is the inverse 
cumulative probability density of the standard normal distribution. We decompose the 
liability li into li=gi+ei, where gi and ei are the genetic and environmental components 
of the liability, respectively. Under standard assumptions,          
   and      
  , 
where    is an    vector of m standardized genetic variants carried by individual i, 
and   is an    vector of effect sizes, which follows the distribution       
  
 
 
  , 
where I is the identity matrix. The genetic and environmental variances   
  and   
  are 
closely related to the narrow-sense heritability of a trait
2
, defined as   
     
    
  . 
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Liability Estimation 
As discussed in the Supplementary Note, testing for associations under the liability 
threshold model requires integrating the underlying liability vector over its support. 
Motivated by this observation, we propose approximating such association testing by 
selecting a liability estimator and treating it as the observed phenotype vector. A good 
liability estimator has values close to the true, unobserved, underlying liability. Thus, 
the problem is equivalent to inferring the value of an unknown continuous variable 
with a known distribution. 
We estimate liabilities via a maximum a posteriori (MAP) estimator, which estimates 
the MAP of the effect sizes of all genetic variants conditional on the phenotypes, 
genotypes and the disease prevalence. The likelihood to maximize can be written as 
       
  
 
 
         
        
  
          
          
        
   
       
         
Taking the logarithm and using the normal distribution definition, the quantity to 
maximize is 
          
        
  
          
              
        
   
       
 
 
   
   
   
 
 
                                                                   
where  is a quantity that does not depend on   and can thus be ignored. This 
problem is equivalent to Probit regression
23
 with L2 regularization and a pre-specified 
offset term, and can thus be solved using standard techniques (Supplementary Note). 
Unlike typical uses of such models, here the regularization parameter is known in 
advance, given a value for   
 . 
The MAP for    is given by      
   , where    is the MAP of  . Given the MAP 
       is equal to    if individual i is a control and      or if individual i is a case and  
    , and is equal to t otherwise. This follows because ei has a zero-mean normal 
distribution. 
 
Dimensionality Reduction 
A straightforward solution of the optimization problem presented above is difficult 
owing to its high dimensionality, which is equal to the number of genotyped variants. 
Fortunately, the problem can be reformulated as a lower dimensional problem, with 
dimensionality equal to the number of individuals. 
The equivalence stems from the fact that the genotypes matrix   can be represented in 
terms of the eigenvectors of its covariance matrix alone. To see this, we rewrite 
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Expression 2 as follows 
      
 
   
   
 
 
                               
where       is a function that depends on   only through the product     Consider 
the singular value decomposition (SVD) of  , given by 
                                                          
where   is the matrix of the eigenvectors of    , and    is orthonormal. Denote 
     and      
  .  Owing to the orthonormality of  , the following equations 
hold: 
  
       
                                            
                                                        
Therefore, Expression 3 can be rewritten as  
       
 
   
   
  
                           
Denoting the number of individuals and genotyped variants by   and , respectively, 
and assuming    and that the columns of   are ordered according to the 
magnitude of their respective eigenvalues, then all columns  of   except for the 
leftmost   ones are equal to zero. Consequently, the vector     depends only on the 
top   entries of the vector   , and thus all the other entries can be set to 0. 
We conclude that the quantity in equation (2) can be maximized by considering only 
the non-zero components of the matrix   and the vector   , which have 
dimensionalities     and  , respectively. In contrast, the original formulation of the 
problem uses the matrix   and the vector  , which have dimensionalities     and 
 , respectively. The original effect sizes are given by      . However, they are 
not needed in practice, since the liabilities estimator can be computed using 
   directly. 
Finally, we note that when performing GWAS, the matrix   is typically computed 
regardless of whether LEAP is employed, and is thus available at no further 
computational cost. This results from the close relation between the SVD of   and the 
eigendecomposition of the matrix    . Namely, given the eigendecomposition 
         , the matrix   is given by     , where   is the matrix of the 
componentwise square roots of the entries of   . In GWAS, the eigendecomposition 
of     is computed both when using an LMM24 and when performing regression 
using principal component covariates
12
, and is thus available for use in LEAP at no 
further computational cost. 
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Use in GWAS 
LEAP uses liability estimates by treating them as observed continuous phenotypes in 
an LMM. Three difficulties that must be dealt with are accurate fitting of the LMM 
parameters, avoiding testing SNPs for association with the liability estimator that they 
helped estimate, and dealing with family relatedness. We now describe solutions to 
these difficulties. 
The difficulty of parameter estimation stems from the non-normality of the liability 
under case-control sampling. This non-normality arises because in rare diseases, the 
majority of cases share a similar liability close to the cutoff. Parameter estimation can 
be suboptimal in such settings.  The most important parameter that is fitted in LMMs 
is the variances ratio     
    
 . Given this parameter, all other parameters can be 
evaluated via closed form formulas
24
. There is a close connection between this 
parameter and the narrow-sense heritability,      
     
    
  , expressed via 
        . We therefore fit this parameter by estimating the heritability using the 
method of ref.
2
, as described in the Supplementary Note. 
A second difficulty arises because SNPs should not be tested for association with a 
liability estimator that they helped estimate. Otherwise the test statistic for these SNPs 
will be inflated, because they can always account for some of the liability variance. 
Similarly, SNPs in linkage disequilibrium with a tested SNP should also not 
participate in the liability estimation. To prevent such inflation, we estimate liabilities 
on a per-chromosome basis. For every chromosome, the liability is estimated using all 
SNPs except for the ones on the chromosome. The SNPs on the excluded 
chromosome are then tested for association using this liability estimator. We note that 
LMM-based GWAS typically compute the eigendecomposition of the covariance 
matrix on a per-chromosome basis as well, in order to prevent a SNP from incorrectly 
affecting the null likelihood (the phenomenon termed proximal contamination
7, 24, 25
). 
LEAP can make use of these available eigendeompositions for dimensionality 
reduction - thus incurring no computational cost other than the liability estimation 
procedure itself. 
A third difficulty arises when the data is confounded by family relatedness. The 
presence of related individuals can lead to biased effect size estimates, and 
consequently to a biased liability estimator. We deal with this difficulty by excluding 
related individuals from the parameter estimation stage of the MAP computation. We 
employ a greedy algorithm, where at each stage we exclude the individual having the 
largest number of related individuals with correlation coefficient >0.05. After fitting 
the model, we estimate liabilities for the excluded individuals as well. We note that 
population structure does not present similar problems, because it is naturally 
captured by top principal components
3, 12, 26
, which are fitted in the MAP computation. 
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Data Simulation 
All experiments reported in this paper are based on a uniform data generation 
procedure that can simulate different settings via a variety of parameters. In these 
simulations, each individual carried 60,100 SNPs that do not affect the phenotype, as 
well as 50-5,000 causal SNPs with normally distributed effect sizes.  Population 
structure was simulated via the Balding-Nichols model
27
, which generates populations 
with genetic divergence measured via Wright's FST
13
. Family relatedness was 
simulated by generating various numbers of sib-pairs in one of the two populations, as 
in ref.
3
. To simulate ascertainment, we generated 3,000/  individuals and a latent 
liability value for every individual, where   is the disease prevalence. We then 
determined the     percentile of the liabilities, and generated new individuals until 
50% of the sample had liabilities exceeding this cutoff
9
. Unless otherwise noted, all 
simulations use 6,000 individuals, FST=0.01 and 30% of the individuals in one of the 
two populations are sibling pairs. In all experiments, ten data sets were generated for 
each unique combination of settings.  A detailed description of the simulation 
procedure and its default parameters is provided in the Supplementary Note. 
 
Software and Code Availability 
LEAP is available to download from https://github.com/omerwe/LEAP. 
LEAP has the same memory requirements as the FaST-LMM package
20
, and is 
computationally efficient.  On a 2 GHz CPU, it can accurately estimate liabilities for samples 
as large as 50,000 individuals in fewer than 5 min. 
21. Yang, J. et al. Nat Genet 42, 565-569 (2010). 
22. Lee, S.H., Wray, N.R., Goddard, M.E. & Visscher, P.M. American journal of human 
genetics 88, 294-305 (2011). 
23. Hastie, T., Tibshirani, R. & Friedman, J. Vol. (Springer, 2009). 
24. Lippert, C. et al. Nature methods 8, 833-835 (2011). 
25. Listgarten, J. et al. Nature methods 9, 525-526 (2012). 
26. Patterson, N., Price, A.L. & Reich, D. PLoS Genet 2, e190 (2006). 
27. Balding, D.J. & Nichols, R.A. Genetica 96, 3-12 (1995). 
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Supplementary Tables 
 
Supplementary Table S1. Type I error rates for synthetic experiments. The table 
shows the type I error rates of the tested methods on synthetic data sets with 6,000 
individuals and 0.1% prevalence, using various FST levels and proportions of 
individuals in one of the two populations who are part of a sib-pair (denoted as S). For 
each method we report its genomic control inflation factor
28
  GC,  defined as the ratio 
of expected to observed median test statistic in    space, and the average ratio of the 
actual type I error rates at p=0.05 and p=10
-5 
over their expected values. For every 
measure we also report its 95% confidence interval (CI), obtained via 1,000 bootstrap 
samples over the test statistics of every data set. Each result is averaged across 10 data 
sets. 
  FST=0.01 S=30% 
  S=0% S=3% S=30% FST=0 FST=0.05 
LEAP 
 GC 0.95 0.96 0.99 0.99 1.03 
 GC CI 0.94-0.97 0.94-0.97 0.98-1.01 0.98-1.01 1.02-1.05 
p=0.05 0.858 0.875 0.950 0.948 0.982 
p=0.05 CI 0.830-0.885 0.848-0.902 0.922-0.979 0.920-0.976 0.954-1.012 
p=10
-5
 0.499 0.832 0.832 0.666 0.666 
p=10
-5
 CI 0.000-1.498 0.000-2.496 0.000-2.496 0.000-1.997 0.000-1.997 
LMM 
 GC 1.00 1.00 1.03 1.03 1.03 
 GC CI 0.98-1.01 0.98-1.01 1.01-1.05 1.01-1.05 1.02-1.05 
p=0.05 0.962 0.972 1.040 1.016 1.041 
p=0.05 CI 0.933-0.991 0.944-1.001 1.010-1.070 0.987-1.046 1.011-1.071 
p=10
-5
 0.666 0.666 1.331 0.832 0.499 
p=10
-5
 CI 0.000-1.830 0.000-1.997 0.000-3.827 0.000-2.329 0.000-1.498 
Linreg
+PCs 
 GC 1.01 1.02 1.06 1.06 1.07 
 GC CI 1.00-1.03 1.01-1.04 1.05-1.08 1.04-1.07 1.05-1.08 
p=0.05 1.007 1.017 1.111 1.099 1.122 
p=0.05 CI 0.978-1.036 0.988-1.047 1.080-1.142 1.069-1.130 1.090-1.152 
p=10
-5
 1.331 1.165 1.165 1.664 1.331 
p=10
-5
 CI 0.000-3.170 0.158-2.995 0.000-3.161 0.000-4.326 0.166-3.328 
Linreg 
 GC 1.56 2.12 1.79 1.06 7.77 
 GC CI 1.54-1.59 2.09-2.15 1.76-1.81 1.04-1.07 7.64-7.89 
p=0.05 2.220 3.220 2.671 1.098 6.042 
p=0.05 CI 2.179-2.260 3.175-3.266 2.627-2.713 1.067-1.129 5.990-6.094 
p=10
-5
 192.3 759.7 359.7 1.331 9314.0 
p=10
-5
 CI 170.0-214.5 719.0-802.2 329.9-389.2 0.000-3.328 9207-9424 
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Supplementary Table S2. Summary statistics and experimental results for the 
multiple sclerosis (MS) and ulcerative colitis (UC) data sets. For each data set, we 
considered two lists of tag SNPs: the list of tag SNPs reported in ref.
7
, and the subset 
of those SNPs with p<0.01 in at least one of the methods. For each method we report 
(a) the ratio between the mean of test statistics of tag SNPs and the corresponding 
mean of a standard LMM and its 95% confidence interval (CI), (b) the mean of the 
ratios of test statistics of tag SNPs with those of a standard LMM, using the subset of 
tag SNPs, and its 95% CI (c) the P value of the ratio of the means, (d) the inflation 
factor  GC, and (e) the ratio of actual type I error rates at p=0.05 and p=10
-5
 over their 
expected values. The type I error rate is computed under the (probably incorrect) 
assumption that a SNP is unassociated with the disease if it is at least 2M base pairs 
away from every previously reported associated SNP. 
  MS UC 
 
 
    Prevalence  0.1% 0.3% 
#cases  10204 2697 
#controls  5429 5652 
#tag SNPs  75 25 
#filtered tag SNPs  44 20 
LEAP 
Ratio of Means 1.04 1.07 
95% CI 1.00-1.09 1.00-1.14 
Mean of Ratios 1.08 1.06 
95% CI 1.01-1.16 0.99-1.13 
P value 0.035 0.027 
 GC 1.18 1.08 
p=0.05 1.46 1.17 
p=10
-5
 13.96 5.64 
LMM 
GC 1.20 1.14 
p=0.05 1.48 1.33 
p=10
-5
 12.72 7.67 
Linreg+PCs 
Ratio of Means 0.91 1.05 
95% CI 0.84-0.98 0.98-1.12 
Mean of Ratios 0.96 1.04 
95% CI 0.89-1.04 0.96-1.12 
P value 0.99 0.10 
 GC 1.26 1.10 
p=0.05 1.60 1.22 
p=10
-5
 39.41 6.32 
Linreg 
Ratio of Means 0.51 1.03 
95% CI 0.44-0.59 0.95-1.12 
Mean of Ratios 0.54 1.04 
95% CI 0.43-0.66 0.95-1.12 
P value 1.00 0.21 
 GC 3.86 1.16 
p=0.05 6.36 1.35 
p=10
-5
 2670.3 7.00 
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Supplementary Table S3. Summary statistics and experimental results for the 
Wellcome Trust 1 data sets. Notations are the same as for Table S2. The phenotypes 
are Crohn's disease (CD), rheumatoid arthritis (RA), type 1 diabetes (T1D), bipolar 
disorder (BD), type 2 diabetes (T2D), coronary artery disease (CAD) and 
hypertension (HT). Results for mean of ratios for HT are not shown because its 
analysis includes only 3 SNPs, yielding an unreliable estimate of this quantity. 
  CD RA T1D BD T2D CAD HT 
         Prevalence  0.1% 0.8% 0.5% 0.5% 5% 6% 30% 
#cases  1726 1834 1945 1850 1902 1905 1926 
#controls  2925 2925 2925 2925 2925 2925 2925 
#tag SNPs  63 31 34 98 41 50 20 
#filtered tag 
SNPs 
 38 11 19 35 17 15 3 
LEAP 
Ratio of Means 1.03 1.04 0.99 1.03 0.98 1.00 0.95 
95% CI 1.00-1.06 1.02-1.07 0.97-1.02 1.00-1.07 0.95-1.01 0.96-1.04 0.86-1.0 
Mean of Ratios 1.03 1.03 0.99 1.05 0.99 1.00 - 
95% CI 1.00-1.07 1.00-1.07 0.96-1.03 1.00-1.11 0.96-1.02 0.94-1.06 - 
P value 0.017 0.002 0.725 0.034 0.924 0.555 0.96 
 GC 1.07 1.02 1.02 1.05 1.02 1.02 0.98 
p=0.05 1.10 1.07 1.05 1.13 1.06 1.02 0.98 
p=10-5 0.41 0.39 0.40 0.00 0.00 0.00 0.40 
LMM 
GC 1.08 1.03 1.04 1.09 1.07 1.08 1.06 
p=0.05 1.13 1.09 1.09 1.22 1.15 1.14 1.15 
p=10-5 0.82 0.00 0.40 0.47 0.83 0.00 1.60 
Linreg+PCs 
Ratio of Means 1.03 1.00 0.98 1.02 0.96 1.00 1.04 
95% CI 0.99-1.06 0.97-1.04 0.96-1.01 0.98-1.07 0.93-1.01 0.96-1.04 0.97-1.16 
Mean of Ratios 1.03 0.99 0.99 1.06 0.99 1.00 - 
95% CI 0.99-1.06 0.95-1.03 0.95-1.02 1.00-1.13 0.95-1.03 0.94-1.06 - 
P value 0.075 0.431 0.928 0.189 0.946 0.514 0.166 
 GC 1.07 1.04 1.04 1.09 1.07 1.07 1.07 
p=0.05 1.11 1.10 1.10 1.23 1.16 1.13 1.18 
p=10-5 0.41 0.78 0.00 0.00 0.42 2.04 2.00 
Linreg 
Ratio of Means 1.03 1.03 0.98 1.06 0.99 1.01 1.02 
95% CI 1.00-1.07 1.00-1.06 0.96-1.01 1.02-1.11 0.96-1.03 0.98-1.05 0.94-1.15 
Mean of Ratios 1.03 1.01 0.98 1.09 1.00 1.01 - 
95% CI 0.99-1.08 0.98-1.05 0.95-1.02 1.03-1.15 0.97-1.04 0.95-1.09 - 
P value 0.055 0.031 0.915 0.003 0.662 0.272 0.357 
 GC 1.11 1.03 1.04 1.12 1.08 1.08 1.07 
p=0.05 1.19 1.11 1.11 1.27 1.18 1.15 1.17 
p=10-5 0.41 0.39 0.00 0.00 1.66 2.04 0.40 
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Supplementary Figures 
 
Supplementary Figure 1: Liability distributions in balanced case-control data 
sets. Individuals with liability greater than the prevalence-specific cutoff are cases, 
and the remainder are controls. The liabilities of controls and of cases follow a zero-
mean normal distribution, conditioned on being smaller or greater than the liability 
cutoff, respectively. The distribution of case liabilities becomes increasingly sharply 
peaked as prevalence decreases. 
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Supplementary Figure 2: Type 1 error rates under different prevalence levels. 
All experiments were run with FST=0.01 and samples where 30% of the individuals 
in one of the two populations are sib-pairs. The gray shaded area is the 95% 
confidence interval of the null distribution. 
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Supplementary Figure 3: Type 1 error rates under different population structure and 
family relatedness levels. 
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Supplementary Figure 4: Power evaluations with different sample sizes, under 
0.1% prevalence. The mean relative increase in power of every method over an 
LMM is shown next to its name, in percentage units.  For example, the number 3 
indicates that a method has average power 3% greater than that of an LMM. Also 
shown is the 95% confidence interval of the mean increase, obtained via 10,000 
bootstrap samples.   
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Supplementary Figure 5: Power evaluations under different prevalence levels, 
with samples of 6,000 individuals. 
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Supplementary Figure 6: Similarity between the estimated and true liabilities of 
controls. The figure shows results for data sets with 6,000 individuals, and their 95% 
confidence intervals (computed via 10-fold cross validation for each data set, 
averaged over 10 data sets). The similarity measures shown are the Pearson 
correlation and the root mean square error, after normalizing the liabilities to have 
zero mean and unit variance. The evaluation was applied only for controls, because 
liabilities of cases are trivial to estimate, as they are tightly clustered near the liability 
cutoff (Fig. S1). 
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Supplementary Figure 7: Power evaluations under different heritability levels. 
 
 
 
Supplementary Figure 8: Population structure experiments. The figure shows the 
mean ratio of normalized test statistics for causal SNPs between each evaluated 
method and an LMM under 0.1% prevalence, 30% sib-pairs, and various population 
structure levels. 
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Supplementary Figure 9: Power evaluations under different population structure 
levels. 
 
 
 
 
Supplementary Figure 10: Family relatedness experiments. The figure shows the 
mean ratio of normalized test statistics for causal SNPs between each evaluated 
method and an LMM under 0.1% prevalence, FST=0.01 and various percentages of 
individuals in one of the two populations who are sib-pairs. 
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Supplementary Figure 11: Power evaluations under different family relatedness levels. 
 
 
Supplementary Figure 12: Polygenicity experiments. The figure shows the mean 
ratio of normalized test statistics for causal SNPs between each evaluated method and 
an LMM under 0.1% prevalence and various numbers of causal SNPs. 
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Supplementary Figure 13: Power evaluations under different numbers of causal 
SNPs. 
 
 
Supplementary Figure 14: The mean ratio of normalized test statistics for causal 
SNPs between each evaluated method and an LMM, in the presence of 
covariates. LEAP+covar is a variant of LEAP that uses covariates as well as genetic 
variants for liability estimation (Supplementary Note 2). 
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Supplementary Figure 15: Power evaluations in the presence of covariates. 
LEAP+covar is a variant of LEAP that uses covariates as well as genetic variants for 
liability estimation (Supplementary Note 2). 
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Supplementary Note 1 - Appendix 
 
 
Comparison of MAP and Posterior Mean Estimators 
LEAP estimates liabilities by finding the maximum a posteriori (MAP) estimate of 
genetic effects for causal variants. Another possible estimator is the posterior mean 
estimator (PME), defined as 
                      
where   is a matrix of genotyped variants,   is a binary vector of observed case-
control phenotypes,    is a vector of genetic effects,   is a vector of iid environmental  
terms and   is the trait prevalence. While the PME cannot be evaluated analytically, it 
can be evaluated numerically via Gibbs sampling
11, 29
. Here we discuss theoretical 
considerations that affect the choice of estimator, and provide an empirical 
comparison of the two estimators under a variety of scenarios. Our empirical 
evaluation demonstrates that the MAP estimator employed by LEAP is more robust to 
the presence of population structure than the PME. For completeness, a Gibbs sampler 
specification is given below. 
From a theoretical perspective, both the PME and the MAP estimator employed by 
LEAP (also termed posterior mode estimator) are point estimates of the liabilities 
vector. According to Bayesian decision theory, the choice of a point estimate is 
dictated by the underlying loss function
30
.  PMEs minimize the mean square error 
(MSE) loss function, whereas MAP estimators minimize a binary loss function that is 
equal to one if the estimated parameters are equal to the true parameters, and zero 
otherwise. Both estimators are consistent and asymptotically unbiased. 
While Bayesian decision theory can guide the choice of estimators in the presence of 
a known probabilistic model, real data often deviates from the underlying model 
assumptions. Recall that according to the liability threshold model, the liability for 
individual   is given by         , where        
   
 
    is the genetic component 
of the liability,    is the effect size of variant  , and    
  is the value of  variant   for 
individual  , standardized to have zero mean and unit variance. The true model holds 
only when all variants are correctly standardized, where the standardized value    
  of 
an observed variant      is given by    
   
         
        
, and        and         are the 
population mean and variance of variant  , respetively. Otherwise, the liability does 
not follow a standard normal distribution. 
When a sample consists of a single homogeneous population, the mean and variance 
of every variant are well defined, and can often be taken from the literature. However, 
GWAS samples are often confounded due to population structure. In such scenarios, 
the correct values depend on the composition of populations in the sample. It is 
difficult to empirically estimate the mean and variance of all variants from a given 
sample, because (a) these values are biased under ascertainment, and (b) even if a 
29 
 
sample is randomly ascertained, the number of variants is typically substantially 
larger than the sample size, leading to a large variance in the estimates of their mean 
and variance.  
Another challenging aspect of empirical estimation of the mean and variance of 
genetic variants, is that the resulting sample covariance matrix (SCM) 
 
 
    is 
singular (where X is a design matrix with standardized columns), because one degree 
of freedom is lost by zero-centering all columns of  .  The PME described in ref.29 
uses the inverse of this matrix, and thus cannot be used in combination with 
standardization based on empirical estimates of the mean and variance. To overcome 
this problem, we regularized the SCM via the well-known Ledoit-Wolf (LW) 
formula
31
. Briefly, given a SCM  , the corresponding regularized covariance matrix 
   is given by 
           
     
 
   
where       is the trace of  ,  is the number of variants,   is the identity matrix and 
  is the optimal shrinkage coefficient that minimizes the mean squared error between 
the estimated and true covariance matrix, whose determination is described by Ledoit 
and Wolf
31
. We note that LEAP also uses a covariance matrix to efficiently compute 
the eigenvalues of the matrix   (Online Methods), but unlike the PME, it can readily 
use the empirical SCM. All experiments described in the main text use the empirical 
SCM. 
We conducted empirical simulations to evaluate the performance of the MAP 
estimator employed by LEAP and the PME described in ref.
29
 under a wide range of 
settings. The data simulation procedure was the same as in all other experiments. We 
evaluated the methods in the presence of a trait with 0.1% prevalence, three levels of 
population structure (corresponding to FST values of 0, 0.01 and 0.05) and three levels 
of family relatedness (corresponding to fraction of sib-pairs of 0%, 3% and 30%).  
Ten data sets were generated for each combination of settings, with 6,000 individuals 
in each data set. The true underlying heritability level of 50% was assumed to be 
known in all simulations, to prevent evaluation bias due to misestimating the 
heritability. The PME was invoked with 10,000 burn-in and 20,000 Gibbs sampler 
iterations (using 10,000 iterations yielded effectively the same results). Evaluation of 
the accuracy of liability estimates was only applied for controls, because liabilities of 
cases are trivial to find for rare diseases, as they are tightly clustered near the liability 
cutoff (Supplementary Fig. S1).  
LEAP was evaluated using both the empirical, the LW regularized and the true 
covariance matrices. The PME was evaluated using only the LW regularized and the 
true covariance matrices, because it cannot be used with the empirical SCM due to the 
singularity noted above. The true covariance matrix was computed by standardizing 
each SNP according to its true mean and variance. These values were computed 
according to the appropriate formulas for a binomially distributed random variable 
with two trials (corresponding to the number of minor alleles) and success probability 
corresponding to the minor allele frequency (MAF). In experiments with population 
structure, we used the MAF corresponding to the mean MAF of the two populations.   
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To prevent biased liability estimation due to family relatedness, we employed a 
greedy algorithm to find the smallest subset of individuals whose removal leaves no 
pair of individuals with correlation coefficient greater than 0.05. The liabilities for 
individuals in this subset were estimated only after fitting the models without 
considering these individuals, as described in the online methods and in ref.
29
. 
The results demonstrate that when there is no population structure, liability estimation 
accuracy is greatest when the true covariance matrix is known (Supplementary Table 
S4). In such cases, LEAP and the PME were equally accurate. When the true 
covariance matrix was unknown, LEAP was always as or more accurate than the 
PME.  In the presence of population structure, use of LEAP with the empirical SCM 
always lead to the greatest accuracy. We note that ref.
29
 proposed dealing with 
population structure by regressing out top principal components from the genotypes 
while adjusting the liability threshold appropriately, but this procedure reduced 
accuracy for both methods (results not shown). 
We conclude that covariance estimation in confounded and ascertained case-control 
studies is a challenging open problem that can substantially affect liability estimation. 
Our experiments demonstrate that the MAP estimator employed by LEAP is more 
robust to model violations than the PME described in ref.
29
, and is thus more suitable 
for liability estimation in the presence of confounding. Another advantage of this 
estimator is its substantially reduced computational cost. We emphasize that although 
the PME used in ref.
29
 cannot use the empirical SCM, potential alternative 
formulations may not suffer from this limitation.  Nevertheless, because MAP results 
are similar whether the empirical or the LW SCM is used, this similarity is likely to 
hold under PMEs as well. 
Supplementary Table S4: Comparison of accuracy of liability estimators, for 
controls only. The evaluated methods are the MAP estimator employed by LEAP, and 
the posterior mean estimator described in ref.
29
. The measures shown are the Pearson 
correlation between the estimated and the true liabilities, and the root mean square 
error. For each measure, the table shows the average, minimum, and maximum values 
obtained across 10 simulated data sets. Both evaluated methods were invoked with 
both the Ledoit-Wolf (LW) regularized and the true covariance matrix. The MAP 
estimator was additionally invoked with the empirical sample covariance matrix. 
Results for methods that obtained an average Pearson correlation at least 0.02 greater 
than the alternative method in the same setting, when using the same covariance 
matrix, are highlighted in bold. 
FST %sibs Covariance Measure MAP Posterior Mean 
0 
0% 
Empirical 
Correlation 0.26 (0.24-0.29) - 
RMSE 1.22 (1.19-1.24) - 
LW 
Correlation 0.26 (0.23-0.29) 0.10 (0.07-0.12) 
RMSE 1.22 (1.19-1.24) 1.34 (1.32-1.37) 
True 
Correlation 0.33 (0.31-0.36) 0.33 (0.31-0.36) 
RMSE 1.16 (1.14-1.18) 1.16 (1.14-1.18) 
3% 
Empirical 
Correlation 0.25 (0.23-0.28) - 
RMSE 1.22 (1.2-1.24) - 
LW 
Correlation 0.25 (0.22-0.27) 0.21 (0.17-0.24) 
RMSE 1.23 (1.21-1.25) 1.26 (1.23-1.29) 
True 
Correlation 0.32 (0.29-0.34) 0.32 (0.28-0.34) 
RMSE 1.17 (1.15-1.20) 1.17 (1.15-1.20) 
31 
 
0 30% 
Empirical 
Correlation 0.33 (0.3-0.36) - 
RMSE 1.16 (1.13-1.18) - 
LW 
Correlation 0.33 (0.3-0.36) 0.10 (0.07-0.15) 
RMSE 1.16 (1.13-1.18) 1.34 (1.30-1.36) 
True 
Correlation 0.38 (0.34-0.41) 0.38 (0.34-0.41) 
RMSE 1.11 (1.08-1.15) 1.11 (1.08-1.15) 
0.01 
0% 
Empirical 
Correlation 0.21 (0.16-0.26) - 
RMSE 1.26 (1.22-1.30) - 
LW 
Correlation 0.19 (0.14-0.25) 0.19 (0.14-0.25) 
RMSE 1.27 (1.22-1.32) 1.27 (1.22-1.32) 
True 
Correlation 0.19 (0.15-0.22) 0.19 (0.15-0.23) 
RMSE 1.27 (1.25-1.31) 1.27 (1.24-1.30) 
3% 
Empirical 
Correlation 0.23 (0.2-0.26) - 
RMSE 1.24 (1.22-1.26) - 
LW 
Correlation 0.21 (0.18-0.25) 0.19 (0.16-0.22) 
RMSE 1.26 (1.23-1.28) 1.28 (1.25-1.30) 
True 
Correlation 0.20 (0.16-0.24) 0.21 (0.17-0.26) 
RMSE 1.26 (1.23-1.3) 1.25 (1.22-1.29) 
30% 
Empirical 
Correlation 0.37 (0.32-0.42) - 
RMSE 1.12 (1.08-1.17) - 
LW 
Correlation 0.36 (0.32-0.4) 0.24 (0.13-0.37) 
RMSE 1.13 (1.09-1.17) 1.23 (1.12-132) 
True 
Correlation 0.33 (0.25-0.42) 0.35 (0.30-0.43) 
RMSE 1.16 (1.08-1.22) 1.14 (1.07-1.18) 
0.05 
0% 
Empirical 
Correlation 0.24 (0.14-0.45) - 
RMSE 1.24 (1.05-1.31) - 
LW 
Correlation 0.23 (0.12-0.45) 0.22 (0.12-0.45) 
RMSE 1.24 (1.05-1.32) 1.24 (1.05-1.32) 
True 
Correlation 0.23 (0.14-0.46) 0.23 (0.14-0.46) 
RMSE 1.24 (1.04-1.31) 1.24 (1.04-1.31) 
3% 
Empirical 
Correlation 0.21 (0.15-0.26) - 
RMSE 1.26 (1.22-1.30) - 
LW 
Correlation 0.20 (0.15-0.25) 0.20 (0.15-0.25) 
RMSE 1.26 (1.23-1.31) 1.27 (1.23-1.31) 
True 
Correlation 0.20 (0.13-0.25) 0.20 (0.13-0.25) 
RMSE 1.26 (1.23-1.32) 1.26 (1.23-1.32) 
30% 
Empirical 
Correlation 0.25 (0.13-0.40) - 
RMSE 1.23 (1.09-1.32) - 
LW 
Correlation 0.25 (0.14-0.40) 0.25 (0.14-0.40) 
RMSE 1.22 (1.09-1.31) 1.22 (1.09-1.31) 
True 
Correlation 0.24 (0.15-0.40) 0.25 (0.15-0.40) 
RMSE 1.23 (1.1-1.31) 1.22 (1.10-1.30) 
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In the remainder of this section, we describe the Gibbs sampler used to estimate the 
posterior mean of the liabilities.  This posterior mean can be estimated by drawing   
pairs of samples           from their posterior distribution for          , and then 
estimating    via 
   
 
 
           
 
   
 
Golan and Rosset
29
 and Hayeck et al.
11
 both recently described a sampling scheme for  
          via a Gibbs sampler. We note that while the formulation described here (in 
notation different from these previous works) is mathematically equivalent to the 
sampler of Golan and Rosset
29
, there are substantial differences in the implementation 
details which can lead to different behaviour in practice, as discussed above. 
Gibbs samplers require specifying the posterior distribution of every sampled random 
variable, conditional on all the other random variable. We therefore derive the 
posterior distribution of each genetic effect    for variant  , and each environmental 
term    for individual  , and demonstrate that each of these follows a truncated normal 
distribution, which can be sampled from efficiently. 
Denoting     as the effect sizes of all variants other than       
        as the 
liability cutoff, encoding      for controls and       for cases, and assuming 
        
  , the posterior distribution of    is given by 
                     
          
  
               
                 
        
  
             
                               
        
  
             
                             
        
  
       
                
 
Here, the inequality            is evaluated component-wise,    is the vector of 
effect sizes composed of     and       and   is the subspace of     wherein       
      holds. This is the definition of the probability density of a truncated normal 
distribution, and so we conclude that    conditional on all other variables follows a 
truncated normal distribution. 
Using similar notations, the posterior distribution for    is given by 
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where   is the subspace of    wherein            holds. As before, we conclude 
that    conditional on all other variables follows a truncated normal distribution. 
 
Runtime Performance 
We implemented the Probit model employed in LEAP in a custom Python package, 
using the scipy.optimize package
32
. On a Linux workstation with an Intel Xeon 
2.90GHz CPU using a single core, the computation for a data set with 8,000 
individuals takes less than five minutes. We note that the computation time is 
independent of the number of SNPs, because it uses the eigendecomposition of the 
genetic similarity matrix, which is already computed by an LMM, and is thus 
available at no additional computational cost. The computations can be sped up by 
computing the Hessian matrix numerically rather than analytically. In this case, the 
computations typically take less than a minute, at a negligible loss of precision. 
In contrast, the computation of the joint MAP (Supplementary Note 3) for such a data 
set typically ranges between 30 and 50 minutes (using the Mosek quadratic solver; 
http://www.mosek.com). The computation of the liabilities posterior mean using 
GeRSI
29
, with 10,000 burn-in iterations and 20,000 sampling iterations, takes 
approximately 45 minutes. 
The reported running times are the times needed to estimate liabilities for a single left-
out chromosome. The effective running time for all methods should be multiplied by 
the number of chromosomes, because a different liability estimator has to be 
estimated for each left-out chromosome. 
 
Insensitivity to Ascertainment in LEAP 
Case-control studies are typically ascertained, having a greater proportion of cases in 
the study than in the general population. The models presented in the methods section 
did not explicitly account for the case-control sampling scheme. However, we show 
here that such a correction is not needed for the models considered. 
Using the notations previously presented, we consider a case-control phenotype vector 
 , a matrix of genetic variants  , a vector of effect sizes  , a vector of environmental 
effects   and a disease with prevalence  . 
We introduce the selection indicators vector  , where      indicates that individual   
was selected to participate in the study, and      otherwise. In practice,       for 
every observed individual, and thus the likelihood of the observed phenotypes is 
conditional on      for every individual. For simplicity, we use the notation     
as a shorthand for                 .  
Our key assumption is that   is conditionally independent of   and  , given   and  . 
This assumption captures many common ascertainment schemes, as described below. 
Under this assumption, we can write the joint MAP maximization problem as 
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where we make use of the conditional independence between   and    . Thus, the 
objective function is equivalent to that of a non-ascertained study. The derivation for 
the genetic MAP estimator is equivalent, with the exception that   is integrated out, as 
described in the main text. 
The posterior mean liabilities are also unaffected by case-control sampling when the 
conditional independence holds. The posterior mean can be written as      
              . Due to the conditional independence, this quantity is equal to 
               , and thus ascertainment does not need to be considered here 
either.  
We caution that insensitivity to ascertainment does not imply that the fitted model is 
equivalent to a model that would have been fitted under a non-ascertained study. 
Rather, insensitivity to ascertainment means that given an ascertained study, a model 
that is fitted without taking the ascertainment procedure explicitly into account is 
equivalent to one that explicitly models the ascertainment scheme. 
We now consider several different ascertainment schemes, and demonstrate that they 
obey the conditional independence assumption. Our derivation make use of graphical 
models theory
33
, which is a rich language for expressing and inferring  conditional 
independencies. Specifically, we consider probabilistic directed acyclic graphical 
models, wherein nodes represent random variables and parameters. According to the 
theory of probabilistic graphical models, two sets of random variables   ,    are 
conditionally independent given a set of random variables  , if no path in the graph 
between a node in    and a node in    obeys the d-connection criterion. A path obeys 
this criterion if (a) every node on the path with two incoming arcs is in   or has a 
descendant in   and (b) there are no nodes on the path that are in  but do not have 
two incoming arcs on this path. 
 
We consider three common ascertainment schemes, derive the appropriate graphical 
model for each one, and demonstrate that the conditional independence holds. 
 
The first ascertainment scheme selects individuals to participate in the study based on 
their phenotype alone. This ascertainment scheme corresponds to Fig. S16a, wherein 
  has a single incoming arc from  . It is easy to verify that paths between   and nodes 
in   do not obey the d-connection criterion. 
 
The second ascertainment scheme selects individuals to participate in the study based 
on their phenotype and genetic ancestry. This can be encoded by introducing a 
population variable   that governs the genotypes distribution, as shown in Fig. S16b. 
As before, no path between   and   follows the d-connection criterion, indicating 
conditional independence. 
 
The third ascertainment scheme selects individuals to participate in the study based on 
their phenotypic and genotypic values. While less common, this ascertainment 
scheme may become more common in the future, as large panels will allow matching 
of cases with similar controls. The resulting model, shown in Fig. S16c, indicates that 
the conditional independence assumption holds. 
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Finally, we note that it is easy to verify that the conditional independence assumption 
holds under a wide variety of different assumptions (e.g., a population-specific 
prevalence, or when the prevalence is treated as an unknown random variable). 
 
 
                      
  (a)      (b) 
 
       
  (c) 
 
Supplementary Figure S16: Probabilistic graphical models for the disease model 
considered in the text. Each node corresponds to a parameter or to a random variable, 
using the same notations as in the text. Gray shaded nodes indicate parameters or 
conditioned variables whose values are known. Each panel shows a different 
ascertainment scheme. In all panels, the model shown is for a data set with 2 
individuals. Panel (a) considers an ascertainment scheme that is determined only 
according to the case-control phenotype. Panel (b) considers an ascertainment scheme 
that considers both the phenotype and the genetic ancestry of an individual. Panel (c) 
considers an ascertainment scheme that considers both the phenotype and genotype of 
an individual. In all cases,   is conditionally independent of the selection variables    
and   , given the genotypes and the phenotypes. 
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Investigating the Causes of Power Loss in Ascertained Case Control Studies 
Here we investigate several possible causes for power loss in LMMs under 
ascertained case-control studies. As discussed in the main text, it has recently been 
discovered that LMM performance in such studies deteriorates with increasing sample 
size, leading to loss of power compared to alternative methods
7
. Yang et al. have 
demonstrated that the severity of power loss in LMMs increases with the ratio 
between the sample size and the effective number of common genetic variants used to 
estimate kinship
7
. This ratio increases with sample size, regardless of genotyping 
density, because the effective number of common variants is bounded and is smaller 
than the number of genotyped variants, owing to linkage disequilibrium
26
. Thus, 
although the absolute power of LMMs increases with sample size, the increase is 
expected to be small compared to alternative methods, owing to model 
misspecification. 
The loss of power of LMMs in ascertained case-control studies stems from violation 
of several of their modelling assumptions. First, LMMs assume that variants have an 
additive effect on the phenotype, which is obviously not true for case-control 
phenotypes.  Second, LMMs assume that genetic and environmental disease factors 
are independent. However, it has recently been demonstrated that these factors 
become correlated under ascertainment, leading to a biased estimation of the genetic 
variance of phenotypes
2
. Third, LMMs assume that variants used to estimate kinship 
are independent of tested variants. However, several recent studies have demonstrated 
that causal variants tend to become correlated under ascertainment, because cases of 
rare diseases are likely to carry high dosages of risk alleles in multiple causal 
variants
7, 9, 10, 34-36.  The first violation is unique to case-control phenotypes, whereas 
the other two are also encountered in ascertained studies of continuous phenotypes. 
To assess the influence of the first model violation on power, we considered an LMM 
which tests for association with the true underlying liabilities. To assess the influence 
of the second violation on power, we considered a "true h
2 
LMM" in which the LMM 
parameter   was fitted according to the true underlying narrow-sense heritability    
via the formula         . This solution applies only to studies of continuous 
phenotypes, because additive narrow-sense heritability is not well defined for case-
control phenotypes. We thus applied this solution only in conjunction with the first 
solution of liability-aware LMMs. We point out that an LMM with knowledge of both 
the true heritability and of the true liabilities represents an idealized version of LEAP, 
where both quantities were perfectly estimated. 
To assess the influence of the third violation on power, we considered an "Oracle 
LMM" which estimates kinship out of all variants except for the causal ones. It is 
impossible to utilize such an LMM in practice, because the true identities of all true 
causal SNPs are unknown. We also considered oracle LMMs with knowledge of the 
true liabilities. We note that oracle LMMs cannot be used with knowledge of the true 
heritability. This is because the true heritability is the proportion to which causal 
variants in the kinship matrix influence the phenotypic variance, whereas there are no 
causal variants in the oracle LMM kinship matrix. We therefore fit the value of   for 
oracle LMMs by maximizing the restricted maximum likelihood of the null model, as 
is common in LMM usage
24
 (the estimated heritability in such cases is different from 
0, because causal and non-causal variants are confounded due to the presence of 
population structure and family relatedness). 
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We evaluated data sets with sample sizes of 2,000, 4,000, 6,000 and 8,000 
individuals, generated as described in the main text, with regular default parameters. 
Specifically, disease prevalence was 0.1% and heritability was 50%. For 
completeness, we also evaluated the performance of linear regression models, both 
with and without using the top 10 principal components as covariates. 
The results are shown in Fig. S17. The largest improvements came from simply using 
the true liabilities, indicating that violations two and three have only a minor effect on 
power loss in continuous phenotype studies. Additional but smaller improvements 
came from use of the oracle LMM and use of the true heritability, along with the true 
liabilities. We conclude that while it is difficult to tease apart a single source of power 
loss, it is clear that liability estimation can greatly mitigate such loss. 
We note that LEAP can be regarded as a noisy version of an LMM with knowledge of 
both the true liabilities and the true heritability, which was the best performing 
method. With increased sample sizes, it is expected that both heritability and 
liabilities can be estimated more accurately, enabling LEAP to more closely resemble 
such an LMM. Thus, the advantage of LEAP over a standard LMM is expected to 
increase with sample size, as demonstrated by the experiments in the main text. 
 
Supplementary Figure S17: Evaluations of factors that drive power loss in 
ascertained studies. All methods were compared to a standard LMM with no 
knowledge of the true causal SNPs, the underlying heritability or the true liabilities. 
 
Complex Ascertainment Schemes 
The experiments described in the main text use a balanced ascertainment scheme and 
uniform trait prevalence, which encode the assumptions that individuals from 
different populations have an equal probability of being sampled, and that the studied 
trait has the same prevalence under different populations, respectively. Here we 
examine the sensitivity of LEAP to deviation from these assumptions. 
We first examined scenarios wherein the ascertainment scheme differs between two 
populations. Specifically, we considered samples where a pre-specified number of 
cases is drawn from one population, and a different number of cases is drawn from the 
second population, such that the total number of individuals from each population is 
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equal to 3,000. We evaluated the performance of LEAP under various levels of 
ascertainment imbalance. Our results indicate that the performance of LEAP improves 
as ascertainment imbalance increases, because the genotypes distribution among cases 
and controls becomes increasingly differentiated, leading to more accurate liability 
estimates (Fig. S18). 
In another experiment, we evaluated the performance of LEAP in the presence of two 
populations with a different prevalence of the studied trait. We simulated data sets 
with two populations having trait prevalence of 0.1% and 1%, respectively, with an 
equal number of cases and controls in each population, and an equal number of 
individuals sampled from each population. LEAP was invoked by specifying the trait 
prevalence as either 0.1%, 0.5% or 1% in the heritability estimation and model fitting 
stages. The performance of LEAP was highly similar in all cases, with an average 
increase in the normalized test statistic of causal SNPs over a standard LMM of 7.8%, 
7.9% and 7.9%, respectively. These results indicate that LEAP is robust to prevalence 
misspecification. 
 
 
Supplementary Figure S18:  Evaluation of GWAS performance in the presence of 
an imbalanced ascertainment scheme, wherein the majority of cases belong to 
population 1. 
 
Comparing LEAP with previous works 
LEAP bears similarities to several recently developed methods for estimating the 
portion of the liability that is explained by a given set of explanatory variables
9, 10
. 
These methods are designed to prevent power loss in ascertained case-control studies 
using covariates, which arises due to induced correlations between tested and 
conditioned variables, as discussed above. However, these methods estimate the 
liability explained by a small set of covariates, whereas LMMs implicitly condition 
association tests on the entire genome, owing to the well known equivalence between  
LMMs and linear regression
37, 38
. A second key difference is that the aforementioned 
methods test variants for association with the residuals of the estimated liabilities, 
after regressing out the influence of the explanatory variables. In contrast, LEAP 
directly tests variants for association with the estimated liabilities, while effectively 
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conditioning on all genome-wide variants. The use of genome-wide variants in both 
the liability estimation and in the association testing stage prevents spurious results 
due to confounding. We empirically verified that testing for association with 
estimated liabilities with either Linreg or Linreg+PCs, or with the estimated residuals 
via LEAP, leads to test statistic inflation (results not shown). 
In parallel work, Hayeck et al. proposed an alternative framework, called LTMLM, 
for association testing under ascertained case-control sampling in the presence of 
confounding
11
. Both LTMLM and LEAP first estimate latent liability values and then 
test for association with these estimates. However, LTMLM tests for association with 
the posterior mean of the liabilities in a score test framework, whereas LEAP tests for 
association with the maximum a posteriori (MAP) of the liabilities. We found that 
utilizing the MAP estimator resulted in improved accuracy over the posterior mean 
estimator under a wide range of scenarios and at a substantially reduced 
computational cost (Methods and Supplementary Note 1). 
 
Accuracy of Liability Estimation 
We demonstrate here that estimation of effect sizes of genetic variants becomes 
increasingly accurate under increasing ascertainment, leading to increasing accuracy 
of liability estimates. We use the probabilistic model derived in the previous sections, 
and consider the MAP of the genetic effects vector  . We show that in balanced case-
control studies, the likelihood function becomes increasingly sharply peaked around 
the MAP of   with decreasing prevalence (and consequently, with increasing 
ascertainment). 
According to standard statistical theory, the sharpness of the likelihood function is 
evaluated via the variance of its score at the MAP of  . The score is the gradient with 
respect to   of the log-likelihood that is maximized in the Probit model. The variance 
of the score becomes equivalent to the Fisher information when there is no 
ascertainment and when   is a fixed (unknown) parameter with no prior distribution. 
A higher score variance indicates that the likelihood function is more sharply peaked 
at the MAP of  , enabling more accurate estimation of  . The variance of the score is 
computed according to the true generative model. This model is similar to the Probit 
model, with the exception that   is integrated out and the ascertainment procedure is 
taken into account. 
Using the same probabilistic model described in the main text and in the previous 
section, the score is defined as 
                  
  
. The log likelihood function is explicitly 
given by 
                 
           
        
  
          
              
        
    
       
 
   
   
   
 
 
   
where   
  is the vector of genetic variants of individual  ,   is a vector of effect sizes, 
  
  is the variance of the environmental component of the liability,   
   is the variance 
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of the genetic component of the liability,   is the number of genetic variants, 
           is the liability cutoff for a disease with prevalence  , and   is a term 
that does not depend on  . The score is therefore given by 
                  
  
   
      
        
  
      
        
  
  
 
          
  
      
        
  
        
        
  
  
 
       
 
 
  
   
   
 
 
The variance of the score is computed according to the true generative model, which 
is similar to the Probit likelihood function, with the exception that   is integrated out 
and there is conditioning on    , using the same definition of   as in the previous 
sections. Therefore, the distribution of   used in the variance computation is 
                
              
            
 
 
            
           
       
          
   
        
              
        
     
       
    
where    and    are the probabilities of including a control or a case in the study, 
respectively. The quantity 
 
           
 is a normalization constant ensuring that the 
probabilities sum to one. 
To demonstrate the effects of ascertainment on the score variance, we created data 
sets with 100 controls, 100 cases and a single binary variant. This formulation 
facilitates variance computations, because every value of the vector   can be 
summarized via the number of controls and cases carrying a risk allele. Consequently, 
the variance can be computed exactly using a quadratic (rather than an exponential) 
number of likelihood computations. The normalization constant is implicitly 
computed by scaling all probabilities to ensure they sum to one. 
We generated data sets with different distributions of the risk allele among cases and 
controls. For each data set we computed the score at the empirical MAP of  , using 
  
       . We used values of      and    
 
   
, which yield an equal mean 
number of sampled cases and controls. The integral was numerically computed using 
1,000 equally spaced samples in the range [-2.5, 2.5].  Table S5 shows the score 
variance for various risk alleles distributions and prevalence values, indicating that the 
score increases with decreasing prevalence (and therefore, with increasing 
ascertainment).  Therefore, more accurate liability estimation is obtained under 
increased ascertainment. 
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Supplementary Table S5: The variance of the score in the presence of a single 
binary variant. A higher score variance indicates that the effect size can be estimated 
more accurately. The values    and    are the fraction of controls and cases carrying 
the risk allele, respectively. For every tested pair of values, we report the score 
variance and the MAP of the variant effect size. 
  Score Variance Effect Size MAP 
      Prevalence Prevalence 
  0.1% 1% 10% 50% 0.1% 1% 10% 50% 
10% 10% 1100.88 528.32 227.58 142.91 0 0 0 0 
10% 20% 1081.98 512.39 222.56 143.30 0.042 0.034 0.024 0.020 
10% 30% 1080.09 507.69 220.98 143.54 0.075 0.060 0.043 0.035 
10% 40% 1085.20 507.60 220.81 143.69 0.103 0.083 0.060 0.049 
10% 50% 1094.77 510.25 221.46 143.79 0.130 0.104 0.075 0.062 
20% 10% 1186.42 557.30 234.83 143.30 -0.044 -0.035 -0.025 -0.020 
20% 20% 1148.47 536.68 228.84 143.38 0 0 0 0 
20% 30% 1132.85 527.58 226.18 143.49 0.035 0.028 0.020 0.016 
20% 40% 1128.43 524.21 225.16 143.59 0.066 0.053 0.038 0.031 
20% 50% 1131.28 524.48 225.19 143.67 0.095 0.076 0.055 0.045 
30% 10% 1224.99 569.45 237.80 143.54 -0.080 -0.063 -0.045 -0.035 
30% 20% 1184.69 549.54 232.15 143.49 -0.036 -0.029 -0.020 -0.016 
30% 30% 1164.43 539.32 229.23 143.52 0 0 0 0 
30% 40% 1155.72 534.62 227.89 143.57 0.032 0.026 0.018 0.015 
30% 50% 1155.06 533.75 227.62 143.62 0.062 0.050 0.036 0.029 
 
 
  
42 
 
Supplementary Note 2 - Detailed Methods 
 
Real Data Processing 
In the WTCCC1 data sets, the control group consisted of individuals from the UK 
Blood Service Control Group (NBS) and from the 1958 British birth cohort. SNPs 
were excluded from the study if they had minor allele frequency <5%, missingness 
rates >1%, a significantly different missingness rate between cases and controls, or a 
significant deviation from Hardy-Weinberg equilibrium among the controls group. 
Individuals were excluded from the analysis if they were in the WTCCC exclusion 
lists or if they had missingness rates>1%.  
In the multiple sclerosis (MS) and ulcerative colitis (UC) data sets, we used the same 
data processing described in ref.
7
 to ensure consistency. Briefly, UK controls and 
cases from both UK and non-UK were used. SNPs were removed with >0.5% missing 
data, p<0.01 for allele frequency difference between two control groups, p<0.05 for 
deviation from Hardy-Weinberg equilibrium, p<0.05 for differential missingness 
between cases and controls, or minor allele frequency<1%. 
In all analyses, SNPs within 5M base pairs of the human leukocyte antigen (HLA) 
region were excluded, because they have large effect sizes and highly unusual linkage 
disequilibrium patterns, which can bias or exaggerate the results
39
. 
 
Methods Evaluation 
Both power and sensitivity to confounding had to be measured in all experiments, 
because not all the evaluated methods properly control for type I error. We used two 
measures for this task. For simulated data, we computed the empirical type I error rate 
associated with each P value, and then computed power as a function of the type I 
error rate. The type I error rate associated with a P value is defined as the proportion 
of non-causal SNPs with P value smaller than this P value. The average power of each 
method was computed by averaging the power corresponding to 1,000 equally spaced 
significance thresholds between 0 and 1 (in log space). Confidence intervals were 
obtained via 10,000 bootstrap samples of test statistics, where test statistics of causal 
and non-causal SNPs were sampled separately to preserve their number. 
For both simulated and real data, we also used another measure that directly compares 
two methods of interest and provides easily interpretable results. To this end, we first 
normalized all test statistics by dividing them with the genomic control (GC) inflation 
factor
28
  GC, defined as the ratio of observed to expected median test statistic in    
space. Afterwards, the ratio between the normalized test statistics obtained by the two 
methods for each known causal variant was computed. The methods were compared 
based on the mean of the ratios. Both proposed evaluation approaches assess 
empirical power given the true type I error rate. However, the first measure simply 
counts the number of test statistics exceeding the significance cutoff (which is 
dependent on sample size), whereas the second one is sensitive to systematic 
differences in the distribution of such test statistics. 
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The second measure employed (the mean of the ratios) is similar to the ratio of the 
means, which is the measure used in refs.
9, 10
. However, the ratio of the means is often 
dominated by excessively large test statistics, whereas the mean of the ratios assigns 
equal importance to all variants.  Additionally, this measure has an intuitive 
interpretation as the mean increase in test statistics of causal variants. Confidence 
intervals for this measure were obtained via 10,000 bootstrap samples of test statistics 
of causal SNPs.  
SNPs having p>0.01 under all methods were discarded from this analysis, because 
they tended to bias the results, while in practice the results for such SNPs are 
meaningless. When not removing these SNPs, LEAP gained an unfair advantage in 
the analysis of real data sets, with a mean ratio of 1.14 for MS, and 1.16 for UC, 
because many such SNPs gain a slightly higher test statistic under LEAP. Such SNPs 
greatly bias the test statistics ratio, despite being meaningless in practice. The ratio of 
the means is relatively unaffected by the exclusion of such SNPs, because it is 
dominated by variants with large test statistics. 
For the analysis of real data, we measured normalized test statistics for known 
associated SNPs. In the MS and UC data sets, we used the list of tag SNPs published 
in ref.
7
. In the analysis of WTCCC1 phenotypes we used best tags from the NHGRI 
catalog
17
 (having the highest r
2
 measure with the causal SNP) as a bronze standard. 
Associated SNPs without a tag SNP having r
2
>0.5 or whose best tag was within 5M 
base pairs of another best tag with a higher statistic were discarded. 
Due to the small number of SNPs with p<0.01 in real data sets, we also report the 
ratio of the means for real data sets, using all tag SNPs. We computed the P value of 
having a ratio of means greater than the actual ratio via permutation testing, by 
swapping the two test statistics computed for a SNP by two different methods one 
million times. 
In the computation of type I error for real data sets (Supplementary Tables S2-S3), 
SNPs within 2M base pairs of a tag SNP were excluded from the analysis. However, 
all SNPs were used for the computation of the genomic inflation factor, to obtain 
measures comparable with previous publications. 
In experiments with covariates, the covariates were not used as fixed effects, because 
this leads to substantial power loss in ascertained case-control studies
10, 34-36
. LEAP 
used covariates by including them in the liability estimation stage and then regressing 
their effect out of the estimated liabilities (Supplementary Note 2). 
 
Simulations Methodology 
To validate our results, we generated synthetic data sets with varying numbers of 
individuals and with 60,100 SNPs that do not affect the phenotype, as well as 50-5000 
SNPs affecting the phenotype. The number of SNPs was selected according to the 
estimated effective number of SNPs in contemporary GWAS samples
7
. The SNPs 
were not in linkage disequilibrium, because it has been shown that the distribution of 
genetic similarity matrices is not affected by its presence
26
. 
We simulated population structure via the Balding-Nichols model
27
, wherein allele 
frequencies in the range [0.05, 0.5] were randomly drawn for an ancestral population, 
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and frequencies for two subpopulations were drawn from a Beta distribution with 
parameters              and                 , where   is the minor allele 
frequency in the ancestral population. Additionally, each data set contained 100 
unusually differentiated SNPs, with an allele frequency difference of 0.6 between the 
two subpopulations (where the allele frequencies for the first subpopulation were 
randomly drawn from [0, 0.4]), to simulate ancient population divergence
40
.   
Family relatedness was simulated by creating sib-pairs (by generating two parents and 
a set of children, assuming all generated SNPs are unlinked) in one of the two 
subpopulations, as in ref.
3
. To combine family relatedness with ascertainment, we first 
created ascertained data sets with no related individuals. We then randomly selected 
pairs of individuals from the ascertained data set and designated them as parents, by 
generating pairs of children for every pair of parents. Afterwards, the two parents 
were removed from the data set. 
Phenotypes were generated using the liability threshold model. Causal SNPs were 
generated for every individual, with effect sizes drawn from a standard normal 
distribution. To simulate differences in the environmental component of the liability 
between the two populations, we also created a hidden causal variable that acts as a 
hidden SNP generated according to the Balding-Nichols model, with an effect size 
drawn from a zero-mean normal distribution with a standard deviation of 5. The 
genetic component of the liability generated for each individual was standardized, so 
that the liability follows a standard normal distribution. The liability cutoff was 
selected by sampling 3,000/K individuals and finding the 1-K percentile of the 
phenotypes, where K is the disease prevalence, as in ref.
9. 
Unless otherwise stated, all data sets were created with 0.1% prevalence, 6,000 
individuals, 50% cases, 50% heritability, FST=0.01, and with 30% of individuals in 
one of the two subpopulations who are sib-pairs. Each individual carried 500 causal 
SNPs with different allele distributions between the two populations according to the 
FST level, one of which was hidden. These SNPs accounted for the genetic component 
of the liability of each individual, according to the specified heritability level. The 
environmental component of the liability for each individual was drawn from a zero-
mean normal distribution, with variance selected to ensure that the liability variance is 
one. 
 
LMM analyses 
LMM analyses were performed with FastLMM 2.0724 using default settings unless 
otherwise stated. In analysis of simulated case-control phenotypes the LMM 
parameter  , which controls the ratio of residual to genetic variance, was fitted only to 
the null model for performance considerations. It has been shown that for typical 
human diseases this approximation often makes a very small difference in practice
39
. 
We empirically verified that fitting   for every SNP yielded almost identical results 
(results not shown). When using liability estimates as phenotypes,   was determined 
according to the liability heritability estimator    , which was estimated using the 
method of ref
2
, with the formula    
 
  
  . 
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When testing synthetic data sets, tested SNPs were excluded from the genetic 
similarity matrix to prevent proximal contamination
7, 24, 25
. In the analysis of real data 
sets, when testing SNPs on a certain chromosome, this chromosome was excluded 
from the LMM genetic similarity matrix to prevent proximal contamination
24, 25
. 
 
Variant Selection 
Several recent papers proposed improving the power of LMMs by estimating kinship 
via a subset of variants that account for a large fraction of the phenotype variance
25, 41, 
42
. This strategy can work well for continuous phenotypes in limited situations
43
. 
However, under ascertained case-control sampling, this strategy renders the problem 
of power loss under LMMs even more severe, because it increases the ratio between 
the number of individuals and the number of variants used by the LMM. Larger 
values of this ratio increase the severity of power loss, as shown in ref.
7
 and in the 
results below (Supplementary Fig. S19). 
We performed a series of experiments to evaluate the effect of variant selection on 
LMM performance, using two variant selection methods that differ in their selection 
criteria. Both methods select a subset of SNPs to be used in the LMM genetic 
similarity matrix (GSM) by first ordering all SNPs according to their univariate linear 
regression P value, and then considering increasingly larger subsets of SNPs having 
the lowest P values. The first method is LMM-select-   , , which selects the smallest 
subset of SNPs that yield a local minimum of the genomic control inflation factor
25
. 
The second variant selection method is LMM-select-pred, which uses the subset of 
variants having the largest out-of-sample predictive power, measured according to the 
predictive log likelihood obtained via five-fold cross validation
41, 42
.  Following the 
recommendation of ref.
41
, we included the top five principal components, associated 
with the five largest eigenvalues, as fixed effects under this selection method. For 
both methods, we evaluated subsets of sizes [1, 5, 10, 15, 20, 30, 40, 50, 75, 100, 250, 
500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 
30000, 40000, 50000, all SNPs]. 
The results demonstrate that under case-control sampling, LMMs using a subset of 
SNPs suffer from a loss of power, whose severity increases as prevalence decreases 
(Supplementary Fig. S19). LMM-select-pred performs poorly under all settings, 
possibly because it directly attempts to select a subset of variants accounting for as 
large as possible fraction of the phenotype variance, which in turn attenuates the 
signal explained by tested variants, leading to loss of power
7
. In contrast, the SNPs 
subset selected by LMM-select-    accounts for a smaller fraction of the phenotype 
variance, which can even improve power under random ascertainment. We therefore 
opted to not follow this strategy in our experiments.  
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Supplementary Figure S19:  Evaluation of variant selection methods. The figure 
shows the mean ratio of normalized test statistics for causal SNPs between each 
evaluated method and an LMM. 
 
Heritability Estimation 
We estimated the heritability of the studied diseases using the method of ref.
2. We 
excluded the top 10 principal components (PCs) from every correlation matrix prior to 
heritability estimation. In experiments with a covariate, the covariate was used as a 
fixed effect in the estimation stage. 
We excluded individuals with at least one correlation coefficient >0.05 with another 
individual, because the method assumes that family relatedness is not present. We 
used a greedy algorithm where at each step the individual with the largest number of 
correlation coefficients >0.05 was removed. However, this procedure was not 
performed for experiments with extreme population structure (FST=0.05), because 
almost all individuals would be excluded, due to the fact that many SNPs have an 
extremely high frequency in one population compared to the other. 
In the analysis of real data, a different heritability estimator was computed for every 
chromosome, because a different liability estimator was provided for every 
chromosome. This was done by considering only SNPs from other chromosomes in 
the computation. In the analysis of synthetic data, SNPs were randomly split into 10 
pseudo-chromosomes, as described in the Liability Estimation section. Heritability 
was estimated for only one pseudo-chromosome, and this estimate was used for the 
liability estimation stage of all pseudo-chromosomes, because it is guaranteed that 
there is no systematic difference between the pseudo-chromosomes. 
 
Liability Estimation 
Liabilities were estimated via a custom implementation of a regularized Probit model, 
described in detail below. For both synthetic and real data, liability estimation was 
performed on a per-chromosome basis. For every chromosome, we estimated the 
liability using only SNPs on other chromosomes. This is meant to guarantee that 
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tested SNPs were not involved in the computation of the liability with which they are 
tested for association. For synthetic data sets, this was done by randomly dividing the 
SNPs into 10 pseudo-chromosomes. We note that typical GWAS also exclude SNPs 
on a given chromosome when testing for association to avoid proximal 
contamination
7, 25
, which requires computing a different eigendeomposition for every 
chromosome. These eigendecomposions, which are also required for efficient 
computation of LEAP, are thus readily available at no further computational cost. 
In the analysis of type I diabetes and rheumatoid arthritis, a single SNP from the HLA 
locus, having the lowest P value out of all SNPs, was used as a covariate in the 
liability estimation, owing to the strong influence of the HLA locus on these 
phenotypes. 
 
Probit Computations 
We estimated liabilities via a Probit model, by using the eigenvectors of the genotype 
matrix   as the design matrix. The Probit model was fitted via Newton's method. This 
is an iterative fitting procedure that makes use of first and second order derivatives, 
defined as: 
         
              
       
 
  
 
             
  
 
where              is the joint posterior density of the effect sizes   and the 
phenotypes  . Denoting   as the matrix of eigenvalues of  , and   as the liability 
cutoff, the first and second order derivatives are given by: 
             
  
     
    
     
    
     
       
    
     
      
     
    
 
     
   
 
  
              
       
       
     
 
   
   
        
     
          
     
     
     
       
    
        
        
           
     
       
      
      
 
 
 
     
  
The initial values    were selected by solving the L2-constrained linear regression 
problem     , using the same regularization parameter as in the Probit model. 
When fitting the models, we excluded individuals having correlation coefficient >0.05 
with at least one other individual, using the same greedy algorithm described earlier 
(except under extreme population structure, as described above). We used the fitted 
parameters to estimate liabilities for all individuals, including the excluded ones. 
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Inclusion of Covariates 
Inclusion of covariates in the LEAP framework presents both technical and statistical 
challenges. These challenges, and our proposed solutions, are described below. 
A technical challenge arises because of numerical instabilities in naive use of 
Newton's method. Naively, Covariates can be included in the Probit model by adding 
additional columns to the design matrix  , without adding corresponding terms to the 
penalty term of the Probit likelihood. However, standard application of Newton's 
method in this case can lead to numerical instabilities because of extreme differences 
in the scaling of columns of the Hessian matrix. To solve this, we perform an iterative 
gradient descent algorithm. At each iteration we fit the random and the fixed effects 
separately via Newton's method. When fitting the random effects (those affecting the 
penalty term) we treat the fixed effects as constants, and vice versa. 
A statistical challenge is encountered because covariates and causal variants tend to 
become highly correlated in ascertained case-control studies. This induced correlation 
takes place because cases of rare diseases often carry high dosages of multiple risk 
variables
10, 34-36
. Furthermore, when fitting covariates as fixed effects, the analysis is 
no longer independent of the ascertainment scheme. 
To exploit the information found in covariates without suffering from power loss and 
having to account for ascertainment, we include them as additional regularized 
random variables in the Probit model, using the same regularization strength as other 
variants. After obtaining a liability estimate, we regress the effect of the covariates out 
of the estimated liabilities, and test for association with this modified liability 
estimator. In the Probit model, the covariates are standardized to have zero mean and 
variance equal to the mean variance of all other variables used in the model.  
We note that additional improvement may be gained by estimating the covariate effect 
size based on information from the literature
10
. 
 
The Joint MAP Estimator 
For estimation of the joint MAP of the genetic and environmental components of the 
liability (Supplementary Note 3), we used the MOSEK quadratic solver 
(http://www.mosek.com). Related individuals were handled in the same way as in 
LEAP. Namely, we first employed a greedy algorithm that excluded related 
individuals from the sample, as previously described. Afterwards, we applied the 
MAP estimator, which fitted a model of effect sizes   and liability environmetal 
components  . Next, We estimated the genetic component   of the excluded 
individuals via      , where    is the matrix of genotypes of excluded 
individuals. Finally, we determined the environmental component   of the excluded 
individuals in the same way as LEAP. We also evaluated a model that did not exclude 
related individuals, which yielded slightly inferior results (results not shown). 
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Supplementary Note 3 - LEAP Overview 
To motivate the use of LEAP, we first introduce the liability threshold model and its 
relation to LMMs. 
 
The Liability Threshold Model 
LEAP originates from the statistical framework of the liability threshold model
8
, 
which is briefly presented here. A key assumption behind this model is that every 
individual   carries a latent normally distributed liability variable          . Cases 
are individuals whose liability exceeds a given cutoff  , i.e.    ≥  .  The cutoff   can 
be inferred given the disease prevalence   as           , where        is the 
inverse cumulative probability density of the standard normal distribution. 
The liability    can be decomposed into two additive terms corresponding to the 
genetic and environmental effects affecting a trait, denoted as    and   :  
                           
Without loss of generalization, we assume that    and    are independently drawn 
from zero-mean normal distributions with variances   
  and   
 , respectively, and thus 
  
    
   . The genetic term    for an individual is given by a linear combination 
of genetic variants and their corresponding effect sizes, 
         
 
   
                     
where    is the effect size of variant   and     is the value of variant   for individual  , 
standardized to have zero mean and unit variance. The effect sizes are assumed to be 
drawn iid from a normal distribution,  
         
                         
When the identities of truly causal variants are unknown, a commonly used 
assumption is that all genotyped variants have an effect size drawn from this normal 
distribution
2
. 
The genetic and environmental effects    and    are deeply related to the narrow-sense 
heritability
2
 of a trait, defined as      
     
    
  . This term is used to quantify 
the degree to which a given trait is affected by genetic factors.  Recently, methods for 
estimating the underlying heritability of the liability of case-control traits have been 
proposed
2, 22
. These methods can be used to estimate the heritability, and consequently 
the variances   
  and   
 . 
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Linear Mixed Models 
To motivate LEAP, we first present the LMM framework. For a given sample of 
individuals, LMMs  assume that an observed phenotypes vector   follows a 
multivariate normal distribution 
        
     
                       
where   is the distribution mean,   is the identity matrix,   is a covariance matrix 
encoding genetic correlations between individuals, and   
 ,   
  are the variances of the 
genetic and environmental components of the covariance, respectively. This model 
naturally encodes the assumption that genetically similar individuals are more likely 
to share similar phenotypes. The genetic covariance matrix   is often estimated from 
genotypes variants as   
 
 
   , where   is a design matrix of genotyped variants, 
standardized so that all columns have zero mean and unit variance. Association testing 
for a given variant   can be carried out by assigning         , where    is the 
variant effect size, and attempting to reject the null hypothesis      by fitting the 
model via restricted maximum likelihood
44
. 
A close relation between the LMM and the liability threshold model is revealed by 
considering the relation between an LMM and linear regression, wherein effect sizes 
are drawn from       
    . Denoting            as the probability density of the 
multivariate normal distribution, and using basic properties of the normal distribution, 
the LMM can be rewritten as follows. 
         
     
           
  
 
 
      
                 
           
  
 
 
              
The phenotypes distribution under LMMs is therefore equivalent to the liability 
distribution under the liability threshold model, after integrating the effect sizes out. 
This interpretation of LMMs provides a straightforward way to extend them to handle 
binary phenotypes. Given a disease with prevalence   and a corresponding liability 
cutoff  , the likelihood for a given case-control status vector   conditional on   is 
given by 
            
    
      
 
 
 
 
 
        
  
 
 
           
        
  
          
            
        
   
        
 
 
 
 
              
where             is the cumulative probability density of the normal distribution, and  
  
  is the i
th
 row of    The relation to the liability threshold model can be made clearer 
by rewriting this likelihood as 
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where          is the underlying liability,   is the subspace wherein   ≥   for 
cases and       for controls, and 
                      
          
  
 
 
              
 
 
 
      
                 
is the liability density. Recall that   
 
 
    is the LMM genetic covariance matrix. 
Thus, computing the likelihood of a case-control phenotype is equivalent to 
integrating the underlying liability over its support. 
The above derivation suggests a natural way to perform association testing in the 
presence of case-control phenotypes. However, this requires fitting the parameters and 
performing a sampling procedure over liability values for every tested variant, 
resulting in excessively expensive computations that are infeasible in most 
circumstances.  
 
Accounting for Ascertainment in Association Testing 
The previous section describes a model for computing the likelihood of a binary 
phenotype under the LMM framework. The presented model does not account for 
fixed effects or for ascertainment, where the proportion of cases in the study is greater 
than the disease prevalence. For completeness, we now derive a model that fully 
accounts for fixed effects  and ascertainment as well. To this end, we use the selection 
variable   introduced in the previous section, and consider a single covariate   (e.g. a 
tested SNP) with a fixed effect  . The extension to multiple covariates is 
straightforward. Using the same notations as before, the likelihood of an observed 
case-control phenotype, conditional on the genotypes, the fixed effect, the disease 
prevalence   and on     is given by 
                                 
            
                
 
where we make use of the common assumption that   is independent of all other 
variables given   and X. The first quantity on the right hand side of this equation is 
the likelihood of the non-ascertained model, whose computation is intractable due to 
having to integrate over a high dimensional subspace of liabilities, as described in the 
main text. 
 
An alternative formulation uses a retrospective approach, where the covariates are 
treated as random, and association testing is carried by computing the likelihood 
conditioned on the phenotype: 
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where again we make use of the conditional independence assumption. Thus, under 
the retrospective likelihood approach, ascertainment does not need to be considered. 
By invoking Bayes rule, we obtain 
                             
          
         
 
As before, the first term on the right hand side is the prospective likelihood, which is 
intractable to compute. Another drawback of this approach is that the genotypes 
distribution needs to be modeled, in contrast to the prospective approach. 
 
 
Liabilities Estimation 
As discussed above, testing for associations under the liability threshold model 
requires integrating the underlying liability vector over its support. Motivated by this 
observation, we propose approximating such association testing by selecting a liability 
estimator and treating it as the observed phenotype vector. A good liability estimator 
has values close to the true, unobserved, underlying liability. Thus, the problem is 
equivalent to inferring the value of an unknown continuous variable with a known 
distribution. 
Recall that the liabilities vector   is given by      , where   and   are the genetic 
and environmental components of the liability, respectively. Further recall that   is 
given by     , where   is the genotypes matrix and   is a vector of effect sizes. 
We consider two closely related liability estimators: The joint maximum a posteriori 
estimate (MAP), and the genetic MAP. The first quantity jointly estimates the 
posterior mode of    and  , conditional on the observed phenotypes, genotypes and 
the disease prevalence. The second quantity first estimates   , the MAP of  , by 
considering   as a nuisance parameter that is integrated out, and then finds the MAP 
of    given    . Although the first quantity has a clearer interpretation, the second 
quantity has favourable properties that render it superior in practice (detailed below), 
and will be used in LEAP. 
Another natural estimator of   is its posterior mean, which can be obtained via 
sampling
11, 29
. Our experiments have demonstrated that, in the presence of population 
structure, the genetic MAP estimator employed by LEAP obtains similar or greater 
liability estimation accuracy, at a significantly reduced computational cost (see 
Supplementary Note 1, Supplementary Fig. S20 and Supplementary Table S4 for a 
thorough investigation of this issue).  
We now describe the derivation and computation of both MAP quantities in detail.  
Importantly, while the derivations below do not explicitly take the case-control 
sampling scheme into account, they yield identical results to derivations that do take 
the ascertainment procedure into account (Supplementary Note 1). Furthermore, while 
the optimization problems derived below are extremely high dimensional, they can 
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readily be formulated as lower-dimensional problems with dimensionality equal to the 
sample size, as described in the next section. Inclusion of covariates is described in 
Supplementary Note 1. 
 
Joint MAP Estimator 
The joint MAP maximizes the joint posterior likelihood of   and  , conditional on the 
phenotypes, genotypes and the disease prevalence. Denoting   as the vector of 
observed case-control phenotypes and   as the disease prevalence, the likelihood to 
maximize can be written as 
                                                                   
where the proportionality sign indicates that the likelihood is scaled by a constant that 
is independent of   and  . Equation 9 makes use of the fact that   and   are 
marginally independent of     and of each other. The probability                is 
a delta function that is equal to one if all cases/controls have liabilities greater/smaller 
than the cutoff           , and zero otherwise. Therefore, using the definitions 
of   and  , computing the MAP is equivalent to solving the optimization problem 
                
  
 
 
           
                                         
where                for controls and        for cases, and the inequality is 
evaluated component-wise. Taking the logarithm, transforming the maximization to a 
minimization, and using the definition of the normal distribution, we obtain the 
equivalent problem: 
         
 
      
   
 
 
 
 
    
   
 
 
                                      
where  is a quantity that does not depend on   or  ,  and can thus be ignored. This 
is a standard quadratic optimization problem, amenable to exact solution using 
standard convex optimization techniques
45
.  Given the joint MAP of   and  ,    is 
given by          . 
 
Genetic MAP Estimator 
The MAP of the effect sizes   can be found by maximizing their posterior likelihood. 
Using the same derivation as before, with the exception that   is integrated out, the 
quantity to maximize is given by 
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Taking the logarithm and using the normal distribution definition, the quantity to 
maximize is 
          
        
  
          
              
        
   
       
 
 
   
   
   
 
 
                                                                    
where  is a quantity that does not depend on   and can thus be ignored. This 
problem is equivalent to Probit regression
23
 with L2 regularization and a pre-specified 
offset term, and can thus be solved using standard techniques (Supplementary Note 
2). Unlike typical uses of such models, here the regularization parameter is known in 
advance, given a value for   
 . 
The MAP    is given by       , where    is the MAP of  . Given the MAP       is 
determined by setting the entries of all cases with     , and all controls with     , 
to be equal to  . All other entries in    are equal to the corresponding entry in   . This 
follows because   has a zero-mean normal distribution. 
We opted to use the genetic MAP estimator, rather than the joint MAP estimator, 
because it is more suitable for liability estimation in the presence of related 
individuals. This greater suitability comes from the way LEAP handles related 
individuals, which consists of first excluding them from the model fitting stage, and 
then estimating their liabilities via the fitted model (see further details below). The 
joint MAP estimator minimizes the in-sample estimation error of the liabilities, 
because it directly fits the environmental component   of individuals participating in 
the fitting stage. In contrast, the genetic MAP estimator attempts to minimize the out-
of-sample estimation error, because it integrates the environmental component   out 
and only fits the effect sizes  . The effect sizes   are later used to estimate liabilities 
for all individuals, including those that did not participate in the model fitting stage. 
Therefore, the genetic MAP estimator is more suitable for the purposes of LEAP. 
We verified empirically that the genetic MAP estimator often yields more accurate 
estimates than either the MAP or the posterior mean estimator (Supplementary Note 
1, Supplemental Fig. S20 and Supplementary Table S4). 
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Supplementary Figure S20:  Comparison of LEAP with the results of GWASs 
performed with different liability estimators: The joint MAP estimator and the 
posterior mean estimator, evaluated via sampling. The results show the ratio between 
the normalized test statistics of each method and a standard LMM. The posterior 
mean estimator used the average of the true frequency of each SNP (between the two 
populations) for covariance estimation, as described in Supplementary Note 1. 
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